Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases-Reference-Cited by-同舟云学术

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

Published:2022-09-07 Issue:13 Volume:29 Page:8597-8605
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Chia Daryl K. A.,Sundar Raghav,Kim Guowei,Ang Jia Jun,Lum Jeffrey H. Y.,Nga Min En,Goh Giap Hean,Seet Ju Ee,Chee Cheng Ean,Tan Hon Lyn,Ho Jingshan,Ngoi Natalie Y. L.,Lee Matilda X. W.,Muthu Vaishnavi,Chan Gloria H. J.,Pang Angela S. L.,Ang Yvonne L. E.,Choo Joan R. E.,Lim Joline S. J.,Teh Jun Liang,Lwin Aung,Soon Yuen,Shabbir Asim,So Jimmy B. Y.^ORCID,Yong Wei Peng

Funder

National Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-11998-z.pdf

Reference31 articles.

1. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7. https://doi.org/10.1002/1097-0142(19890115)63:2%3c364::aid-cncr2820630228%3e3.0.co;2-v.

2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.

3. Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19–33. https://doi.org/10.1093/annonc/mdy502.

4. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.

5. de Bree E, Michelakis D, Stamatiou D, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum. 2017;2(2):47–62. https://doi.org/10.1515/pp-2017-0010.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases;Gastroenterology;2024-08

2. Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative);European Journal of Surgical Oncology;2024-07

3. Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis;British Journal of Surgery;2024-05

4. Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases;2024-03-28

5. Re: Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European Consensus project on the definition and treatment for oligometastatic esophagogastric cancer;ESMO Gastrointestinal Oncology;2024-03